PE20020062A1 - 5-AMINO-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA COMO ANTAGONISTAS RECEPTORES DE ADENOSINA A2a - Google Patents
5-AMINO-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA COMO ANTAGONISTAS RECEPTORES DE ADENOSINA A2aInfo
- Publication number
- PE20020062A1 PE20020062A1 PE2001000475A PE2001000475A PE20020062A1 PE 20020062 A1 PE20020062 A1 PE 20020062A1 PE 2001000475 A PE2001000475 A PE 2001000475A PE 2001000475 A PE2001000475 A PE 2001000475A PE 20020062 A1 PE20020062 A1 PE 20020062A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- phenyl
- halogen
- triazolo
- pyrazolo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
SE REFIERE A COMPUESTOS 5-AMINO-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA DE FORMULA I DONDE R ES R1-FURANILO, R1-TIENILO, R1-PIRIDILO, ENTRE OTROS; X ES ALQUILENO, COCH2; Y ES NR2CH2CH2NR3, OCH2CH2NR2, O, S, CH2S, (CH2)2NH, GRUPO a; m Y n SON 2-3; Q ES N, CH, COH, ENTRE OTROS; Z ES R5-FENILO, R5-FENILALQUILO, R5-HETEROARILO, DIFENILMETILO, GRUPO b, R6CO, ENTRE OTROS; Z E Y SON PIPERIDINILO, FENILO, GRUPO c; R1 ES H, ALQUILO C1-C6, CF3, HALOGENO, NO2; R2, Y R3 SON H, ALQUILO C1-C6; R4 ES H, ALQUILO C1-C6; R5 ES H, HALOGENO, ALQUILO C1-C6, OH, ALCOXI C1-C6, ENTRE OTROS; R6 ES ALQUILO C1-C6, R5-FENILO, TIENILO, ENTRE OTROS; R7 ES ALQUILO C1-C6, R5-FENILO, ENTRE OTROS; R8 ES H, ALQUILO C1-C6 O R7 Y R8 SON (CH2)p-A-(CH2)q; p Y q SON 2-3; A ES UN ENLACE, CH2, S, O; R9 ES H, ALQUILO C1-C6, OH, ALCOXI C1-C6, HALOGENO, ENTRE OTROS; R10 ES H, HALOGENO, ALQUILO C1-C6, ENTRE OTROS; R11 ES H, ALQUILO C1-C6, FENILO, ENTRE OTROS; R12 ES H, ALQUILO C1-C6; R13 ES ALQUILO C1-C6-CO, ALQUILO C1-C6-SO2. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS I SON ANTAGONISTAS DE RECEPTORES DE ADENOSINA A2a Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE DEPRESION, ENFERMEDADES COGNITIVAS, ENFERMEDADES NEURODEGENERATIVAS, APOPLEJIA, PARKINSON
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20714300P | 2000-05-26 | 2000-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020062A1 true PE20020062A1 (es) | 2002-02-02 |
Family
ID=22769372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000475A PE20020062A1 (es) | 2000-05-26 | 2001-05-24 | 5-AMINO-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA COMO ANTAGONISTAS RECEPTORES DE ADENOSINA A2a |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US6630475B2 (es) |
| EP (1) | EP1283839B1 (es) |
| JP (3) | JP4574112B2 (es) |
| KR (1) | KR100520907B1 (es) |
| CN (2) | CN100384847C (es) |
| AR (1) | AR028621A1 (es) |
| AT (1) | ATE293627T1 (es) |
| AU (2) | AU2001268089C1 (es) |
| BR (1) | BRPI0111015B8 (es) |
| CA (1) | CA2410237C (es) |
| CZ (1) | CZ303790B6 (es) |
| DE (1) | DE60110219T2 (es) |
| DK (1) | DK1283839T3 (es) |
| EC (1) | ECSP024364A (es) |
| ES (1) | ES2237576T3 (es) |
| HK (1) | HK1049007B (es) |
| HU (1) | HU230420B1 (es) |
| IL (3) | IL152726A0 (es) |
| MX (1) | MXPA02011625A (es) |
| MY (1) | MY132006A (es) |
| NO (1) | NO325008B1 (es) |
| NZ (1) | NZ522326A (es) |
| PE (1) | PE20020062A1 (es) |
| PL (1) | PL218764B1 (es) |
| PT (1) | PT1283839E (es) |
| RU (1) | RU2315053C2 (es) |
| SI (1) | SI1283839T1 (es) |
| SK (1) | SK287748B6 (es) |
| TW (1) | TWI288137B (es) |
| WO (1) | WO2001092264A1 (es) |
| ZA (1) | ZA200208898B (es) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2410237C (en) * | 2000-05-26 | 2008-01-08 | Schering Corporation | Adenosine a2a receptor antagonists |
| EP1425017A1 (en) * | 2001-09-13 | 2004-06-09 | Schering Corporation | Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic |
| CN100421663C (zh) | 2001-10-15 | 2008-10-01 | 先灵公司 | 咪唑并（4,3－E）,1,2,4－三唑并（1,5－C）嘧啶类化合物作为腺苷A2a受体拮抗剂 |
| FR2832405B1 (fr) * | 2001-11-19 | 2004-12-10 | Sanofi Synthelabo | Tetrahydropyridyl-alkyl-heterocycles azotes, procede pour leur preparation et compositions pharmaceutiques les contenant |
| CA2468649C (en) * | 2001-11-30 | 2009-03-10 | Schering Corporation | Adenosine a2a receptor antagonists |
| HUP0402324A3 (en) | 2001-11-30 | 2008-09-29 | Schering Corp | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine derivatives as adenosine a2a receptor antagonists and pharmaceutical compositions containing them |
| PE20030739A1 (es) | 2001-11-30 | 2003-08-28 | Schering Corp | Antagonistas del receptor de adenosina a2a |
| KR101166000B1 (ko) | 2002-01-28 | 2012-07-16 | 교와 핫꼬 기린 가부시키가이샤 | 운동성 질환에 걸린 환자의 치료 방법 |
| AU2003245380A1 (en) * | 2002-05-30 | 2003-12-19 | King Pharmaceuticals Research & Development, Inc. | Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use |
| US20060106040A1 (en) * | 2002-12-19 | 2006-05-18 | Michael Grzelak | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
| CN100415217C (zh) * | 2002-12-19 | 2008-09-03 | 先灵公司 | 腺苷A2a受体拮抗剂的应用 |
| US20070010522A1 (en) | 2003-04-09 | 2007-01-11 | Chi Vu | Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists |
| AR044041A1 (es) * | 2003-04-23 | 2005-08-24 | Schering Corp | Antagonistas del receptor a2a de 2-alquinil- y 2-alquenil-pirazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pirimidina adenosina |
| BRPI0411120A (pt) * | 2003-06-10 | 2006-07-18 | Kyowa Hakko Kogyo Kk | método para tratar de um distúrbio de ansiedade, composição, agente para tratar de um distúrbio de ansiedade, e, usos de um composto e de um derivado de xantina |
| EP1636187A1 (en) * | 2003-06-12 | 2006-03-22 | Novo Nordisk A/S | Substituted piperazine carbamates for use as inhibitors of hormone sensitive lipase |
| WO2005039506A2 (en) * | 2003-10-24 | 2005-05-06 | Exelixis, Inc. | P70s6 kinase modulators and method of use |
| DE602004004677T2 (de) | 2003-10-28 | 2007-11-15 | Schering Corp. | Verfahren zur Herstellung substituierter 5-Amino-Pyrazolo-(4,3-E)-1,2,4-Triazo lo (1,5-C)Pyrimidine |
| DE602004009962T2 (de) | 2003-12-01 | 2008-08-28 | Schering Corp. | Verfahren zur herstellung von substituierten 5-aminopyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidinen |
| AU2004303425C1 (en) * | 2003-12-19 | 2010-02-18 | Schering Corporation | Pharmaceutical compositions |
| JP2007533754A (ja) | 2004-04-21 | 2007-11-22 | シェーリング コーポレイション | ピラゾロ−［４，３−ｅ］−１，２，４−トリアゾロ−［１，５−ｃ］−ピリミジンアデノシンＡ２ａレセプターアンタゴニスト |
| ES2385702T3 (es) * | 2005-06-07 | 2012-07-30 | Kyowa Hakko Kirin Co., Ltd. | Antagonistas de A2A para uso en el tratamiento de trastornos de la motricidad |
| WO2007035542A1 (en) | 2005-09-19 | 2007-03-29 | Schering Corporation | 2-HETEROARYL-PYRAZOLO-[4, 3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| AR056080A1 (es) * | 2005-09-23 | 2007-09-19 | Schering Corp | 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine |
| ES2273599B1 (es) | 2005-10-14 | 2008-06-01 | Universidad De Barcelona | Compuestos para el tratamiento de la fibrilacion auricular. |
| JP5539717B2 (ja) * | 2006-07-14 | 2014-07-02 | 塩野義製薬株式会社 | オキシム化合物およびその使用 |
| TW200840566A (en) * | 2006-12-22 | 2008-10-16 | Esteve Labor Dr | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments |
| US7723343B2 (en) | 2007-03-30 | 2010-05-25 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2A receptor antagonists |
| WO2009110955A2 (en) * | 2008-02-29 | 2009-09-11 | Albert Einstein College Of Medicine Of Yeshiva University | Ketoconazole-derivative antagonists of human pregnane x receptor and uses thereof |
| JP2011513417A (ja) | 2008-03-04 | 2011-04-28 | シェーリング コーポレイション | アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物 |
| US20110064671A1 (en) | 2008-03-10 | 2011-03-17 | Cornell University | Modulation of blood brain barrier permeability |
| TWI473614B (zh) * | 2008-05-29 | 2015-02-21 | Kyowa Hakko Kirin Co Ltd | Anti-analgesic inhibitors |
| WO2010010908A1 (ja) * | 2008-07-23 | 2010-01-28 | 協和発酵キリン株式会社 | 片頭痛治療剤 |
| US20100093702A1 (en) * | 2008-10-13 | 2010-04-15 | Barbay J Kent | METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| TW201036614A (en) | 2008-12-30 | 2010-10-16 | Arqule Inc | Substituted 1H-pyrazolo[3,4-d]pyrimidine-6-amine compounds |
| EP2389175A1 (en) | 2009-01-20 | 2011-11-30 | Schering Corporation | Methods of alleviating or treating signs and/or symptoms associated with moderate to severe parkinson's disease |
| WO2010084160A1 (en) | 2009-01-21 | 2010-07-29 | Oryzon Genomics S.A. | Phenylcyclopropylamine derivatives and their medical use |
| JP5765239B2 (ja) | 2009-03-13 | 2015-08-19 | アドヴィナス・セラピューティックス・リミテッド | 置換縮合ピリミジン化合物 |
| CA2756871A1 (en) | 2009-03-31 | 2010-10-07 | Arqule, Inc. | Substituted heterocyclic compounds |
| US8537177B2 (en) * | 2009-06-15 | 2013-09-17 | Marvell World Trade Ltd. | System and methods for gamut bounded saturation adaptive color enhancement |
| WO2011017299A2 (en) | 2009-08-07 | 2011-02-10 | Schering Corporation | PROCESS FOR PREPARING A 2-ALKYNYL SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE |
| KR101736218B1 (ko) | 2009-09-25 | 2017-05-16 | 오리존 지노믹스 에스.에이. | 라이신 특이적 디메틸라아제-1 억제제 및 이의 용도 |
| US8946296B2 (en) | 2009-10-09 | 2015-02-03 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use |
| WO2011101861A1 (en) | 2010-01-29 | 2011-08-25 | Msn Laboratories Limited | Process for preparation of dpp-iv inhibitors |
| WO2011106105A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Inhibitors for antiviral use |
| US9186337B2 (en) | 2010-02-24 | 2015-11-17 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae |
| WO2011131697A1 (en) | 2010-04-19 | 2011-10-27 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
| US9181198B2 (en) | 2010-07-29 | 2015-11-10 | Oryzon Genomics S.A. | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use |
| WO2012013727A1 (en) | 2010-07-29 | 2012-02-02 | Oryzon Genomics S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| CA2812378C (en) * | 2010-09-24 | 2016-11-29 | Advinus Therapeutics Limited | Fused tricyclic compounds as adenosine receptor antagonist |
| WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
| EP2712315B1 (en) | 2011-02-08 | 2021-11-24 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
| WO2012129381A1 (en) * | 2011-03-22 | 2012-09-27 | Concert Pharmaceuticals Inc. | Deuterated preladenant |
| WO2012127472A1 (en) * | 2011-03-22 | 2012-09-27 | Mapi Pharma Ltd. | Process and intermediates for the preparation of preladenant and related compounds |
| WO2013024474A1 (en) * | 2011-08-18 | 2013-02-21 | Mapi Phrarma Ltd. | Polymorphs of preladenant |
| KR102139537B1 (ko) | 2011-10-20 | 2020-07-31 | 오리존 지노믹스 에스.에이. | Lsd1 억제제로서 (헤테로)아릴 사이클로프로필아민 화합물 |
| MY187638A (en) | 2011-10-20 | 2021-10-06 | Oryzon Genomics Sa | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| WO2014071512A1 (en) * | 2012-11-06 | 2014-05-15 | Universite Laval | Combination therapy and methods for the treatment of respiratory diseases |
| WO2014101120A1 (en) * | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
| EP3220910B1 (en) | 2014-11-18 | 2020-01-15 | Merck Sharp & Dohme Corp. | Aminopyrazine compounds with a2a antagonist properties |
| WO2016126570A1 (en) | 2015-02-06 | 2016-08-11 | Merck Sharp & Dohme Corp. | Aminoquinazoline compounds as a2a antagonist |
| EP3307067B1 (en) | 2015-06-11 | 2022-11-02 | Merck Sharp & Dohme LLC | Aminopyrazine compounds with a2a antagonist properties |
| WO2017008205A1 (en) | 2015-07-10 | 2017-01-19 | Merck Sharp & Dohme Corp. | Substituted aminoquinazoline compounds as a2a antagonist |
| US9675585B1 (en) | 2016-03-24 | 2017-06-13 | Ezra Pharma | Extended release pharmaceutical formulations |
| US9687475B1 (en) | 2016-03-24 | 2017-06-27 | Ezra Pharma Llc | Extended release pharmaceutical formulations with controlled impurity levels |
| TWI801372B (zh) * | 2017-03-30 | 2023-05-11 | 比利時商艾特歐斯比利時有限公司 | 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法 |
| IL300149A (en) * | 2017-03-30 | 2023-03-01 | iTeos Belgium SA | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers |
| WO2019118313A1 (en) | 2017-12-13 | 2019-06-20 | Merck Sharp & Dohme Corp. | Imidazo [1,2-c] quinazolin-5-amine compounds with a2a antagonist properties |
| EP3735413B1 (en) * | 2018-01-04 | 2022-07-06 | Impetis Biosciences Ltd. | Tricyclic compounds, compositions and medicinal applications thereof |
| MA52422A (fr) | 2018-02-27 | 2021-01-06 | Incyte Corp | Imidazopyrimidines et triazolopyrimidines en tant qu'inhibiteurs a2a/a2b |
| CN108276345A (zh) * | 2018-03-22 | 2018-07-13 | 重庆奥舍生物化工有限公司 | 一种药物中间体嘧啶-5-甲醛的制备方法 |
| MX2020010618A (es) * | 2018-04-08 | 2020-11-12 | Beigene Ltd | Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a. |
| JP7391046B2 (ja) | 2018-05-18 | 2023-12-04 | インサイト・コーポレイション | Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体 |
| CN108864114B (zh) * | 2018-06-04 | 2020-11-06 | 应世生物科技(南京)有限公司 | 选择性a2a受体拮抗剂 |
| UA128332C2 (uk) | 2018-07-05 | 2024-06-12 | Інсайт Корпорейшн | Похідні конденсованих піразинів як інгібітори a2a/a2b |
| CN110742893B (zh) * | 2018-07-23 | 2024-04-05 | 百济神州(北京)生物科技有限公司 | A2a受体拮抗剂治疗癌症的方法 |
| MA54298A (fr) | 2018-11-30 | 2022-03-09 | Merck Sharp & Dohme | Dérivés amino triazolo quinazoline 9-substitués utiles en tant qu'antagonistes du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation |
| US11459329B2 (en) | 2018-12-20 | 2022-10-04 | Incyte Corporation | Imidazopyridazine and imidazopyridine compounds and uses thereof |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| WO2020227156A1 (en) * | 2019-05-03 | 2020-11-12 | Nektar Therapeutics | Adenosine 2 receptor antagonists |
| DE102019116986A1 (de) | 2019-06-24 | 2020-12-24 | Helmholtz-Zentrum Dresden-Rossendorf E. V. | Deuterierte 7-(3-(4-(2-([18F]Fluor)ethoxy)phenyl)propyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amin-Derivate |
| US20230024108A1 (en) * | 2019-07-17 | 2023-01-26 | Teon Therapeutics, Inc. | Adenosine a2a receptor antagonists |
| CN112479956A (zh) | 2019-07-30 | 2021-03-12 | 杭州阿诺生物医药科技有限公司 | 一种用于制备腺苷受体抑制剂中间体的方法 |
| CN112625050B (zh) | 2019-07-30 | 2021-10-01 | 杭州阿诺生物医药科技有限公司 | 一种a2a和/或a2b受体抑制剂的制备方法 |
| CN111072675A (zh) * | 2019-12-12 | 2020-04-28 | 广东东阳光药业有限公司 | 含氮稠合三环衍生物及其用途 |
| JP7431665B2 (ja) | 2020-05-20 | 2024-02-15 | Ykk Ap株式会社 | 接合構造および建具 |
| CN113773327B (zh) * | 2021-09-13 | 2022-07-15 | 八叶草健康产业研究院(厦门)有限公司 | 一种吡唑并嘧啶并三唑环类化合物的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU466232A1 (ru) * | 1973-05-23 | 1975-04-05 | Киевский Ордена Ленина Государственный Университет Им.Т.Г.Шевченко | Споссоб получени конденсированных пиримидо- -триазиниевых соединений с мостиковыми атомами азота |
| EP0217748B1 (en) | 1985-09-30 | 1991-02-06 | Ciba-Geigy Ag | 2-Substituted-e-fused-[1,2,4,]triazolo-[1,5-c]pyrimidines pharmaceutical compositions and uses thereof |
| SU1739850A3 (ru) * | 1987-08-31 | 1992-06-07 | Такеда Кемикал Индастриз, Лтд (Фирма) | Способ получени конденсированных производных пиразоло[3,4- @ ]пиримидина |
| IT1264901B1 (it) * | 1993-06-29 | 1996-10-17 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina |
| CA2144330A1 (en) | 1993-07-27 | 1995-02-09 | Fumio Suzuki | A therapeutic agent for parkinson's disease |
| IT1277392B1 (it) * | 1995-07-28 | 1997-11-10 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina |
| IT1291372B1 (it) * | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
| CA2410237C (en) * | 2000-05-26 | 2008-01-08 | Schering Corporation | Adenosine a2a receptor antagonists |
| CA2468649C (en) * | 2001-11-30 | 2009-03-10 | Schering Corporation | Adenosine a2a receptor antagonists |
| CN100415217C (zh) * | 2002-12-19 | 2008-09-03 | 先灵公司 | 腺苷A2a受体拮抗剂的应用 |
| DE602004004677T2 (de) * | 2003-10-28 | 2007-11-15 | Schering Corp. | Verfahren zur Herstellung substituierter 5-Amino-Pyrazolo-(4,3-E)-1,2,4-Triazo lo (1,5-C)Pyrimidine |
| DE602004009962T2 (de) * | 2003-12-01 | 2008-08-28 | Schering Corp. | Verfahren zur herstellung von substituierten 5-aminopyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidinen |
| JP2007533754A (ja) * | 2004-04-21 | 2007-11-22 | シェーリング コーポレイション | ピラゾロ−［４，３−ｅ］−１，２，４−トリアゾロ−［１，５−ｃ］−ピリミジンアデノシンＡ２ａレセプターアンタゴニスト |
| WO2007035542A1 (en) * | 2005-09-19 | 2007-03-29 | Schering Corporation | 2-HETEROARYL-PYRAZOLO-[4, 3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
-
2001
- 2001-05-24 CA CA002410237A patent/CA2410237C/en not_active Expired - Lifetime
- 2001-05-24 EP EP01945991A patent/EP1283839B1/en not_active Expired - Lifetime
- 2001-05-24 SI SI200130336T patent/SI1283839T1/xx unknown
- 2001-05-24 SK SK1671-2002A patent/SK287748B6/sk not_active IP Right Cessation
- 2001-05-24 US US09/865,071 patent/US6630475B2/en not_active Ceased
- 2001-05-24 PL PL360472A patent/PL218764B1/pl unknown
- 2001-05-24 MY MYPI20012466A patent/MY132006A/en unknown
- 2001-05-24 AU AU2001268089A patent/AU2001268089C1/en not_active Expired
- 2001-05-24 NZ NZ522326A patent/NZ522326A/xx not_active IP Right Cessation
- 2001-05-24 TW TW090112461A patent/TWI288137B/zh not_active IP Right Cessation
- 2001-05-24 AR ARP010102483A patent/AR028621A1/es active IP Right Grant
- 2001-05-24 PT PT01945991T patent/PT1283839E/pt unknown
- 2001-05-24 PE PE2001000475A patent/PE20020062A1/es active IP Right Grant
- 2001-05-24 CN CNB2006100049297A patent/CN100384847C/zh not_active Expired - Lifetime
- 2001-05-24 JP JP2002500877A patent/JP4574112B2/ja not_active Expired - Lifetime
- 2001-05-24 IL IL15272601A patent/IL152726A0/xx unknown
- 2001-05-24 AT AT01945991T patent/ATE293627T1/de active
- 2001-05-24 KR KR10-2002-7015699A patent/KR100520907B1/ko not_active Expired - Lifetime
- 2001-05-24 BR BRPI0111015-2 patent/BRPI0111015B8/pt not_active IP Right Cessation
- 2001-05-24 CN CNB018134491A patent/CN1247588C/zh not_active Expired - Lifetime
- 2001-05-24 ES ES01945991T patent/ES2237576T3/es not_active Expired - Lifetime
- 2001-05-24 DE DE60110219T patent/DE60110219T2/de not_active Expired - Lifetime
- 2001-05-24 WO PCT/US2001/016954 patent/WO2001092264A1/en active Application Filing
- 2001-05-24 HU HU0600239A patent/HU230420B1/hu unknown
- 2001-05-24 CZ CZ20023886A patent/CZ303790B6/cs not_active IP Right Cessation
- 2001-05-24 AU AU6808901A patent/AU6808901A/xx active Pending
- 2001-05-24 DK DK01945991T patent/DK1283839T3/da active
- 2001-05-24 MX MXPA02011625A patent/MXPA02011625A/es active IP Right Grant
- 2001-05-24 RU RU2002135620/04A patent/RU2315053C2/ru active
-
2002
- 2002-11-01 ZA ZA200208898A patent/ZA200208898B/en unknown
- 2002-11-10 IL IL152726A patent/IL152726A/en active IP Right Grant
- 2002-11-25 NO NO20025651A patent/NO325008B1/no not_active IP Right Cessation
- 2002-11-25 EC EC2002004364A patent/ECSP024364A/es unknown
-
2003
- 2003-02-21 HK HK03101315.3A patent/HK1049007B/zh not_active IP Right Cessation
- 2003-05-30 US US10/448,854 patent/US6897216B2/en not_active Expired - Lifetime
-
2004
- 2004-08-06 US US10/912,834 patent/US7067655B2/en not_active Expired - Lifetime
-
2006
- 2006-05-02 JP JP2006128415A patent/JP4938348B2/ja not_active Expired - Lifetime
-
2007
- 2007-03-16 JP JP2007069618A patent/JP2007145875A/ja not_active Withdrawn
-
2012
- 2012-04-06 US US13/441,140 patent/USRE44205E1/en not_active Expired - Lifetime
- 2012-06-04 IL IL220174A patent/IL220174A/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020062A1 (es) | 5-AMINO-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA COMO ANTAGONISTAS RECEPTORES DE ADENOSINA A2a | |
| PE20030477A1 (es) | ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a | |
| PE20060185A1 (es) | ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA | |
| PE20051039A1 (es) | [1,8] naftiridin-2-onas y compuestos relacionados | |
| CO5700778A2 (es) | Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular | |
| PE20020366A1 (es) | Derivados de piperazina como ligandos del receptor 5ht2 | |
| PE20030739A1 (es) | Antagonistas del receptor de adenosina a2a | |
| AR004516A1 (es) | Derivados de pirimidina, su uso, procedimientos para prepararlos y medicamentos que los contienen | |
| PE20081192A1 (es) | Tratamiento del dolor | |
| PE20010629A1 (es) | Derivados de triazolpiridinamina como ligandos de receptores de adenosina | |
| PE20130012A1 (es) | Derivados de pirazol como inhibidores de jak | |
| PE20030129A1 (es) | Imidazotriazinas | |
| PE46899A1 (es) | Derivados de n-fenil-sulfonamida | |
| PE20040197A1 (es) | Pirazolopiridinas sustituidas con carbamato | |
| PE20010964A1 (es) | Derivados de tiazolilamida | |
| AR072756A2 (es) | Intermediarios para la preparacion; derivados de triazolo[4,5-d]pirimidina, utiles como antitromboticos | |
| PE20020406A1 (es) | 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS 2,6-DISUSTITUIDAS COMO INHIBIDORES DE LAS PROTEINAS CINASAS | |
| PE20030727A1 (es) | 17OALQUIL-17ß-OXI-ESTRATRIENOS, PRODUCTOS INTERMEDIARIOS PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN | |
| PE20030431A1 (es) | DERIVADOS QUINUCLIDINAS COMO AGONISTAS DEL RECEPTOR NICOTINICO DE LA ACETILCOLINA TIPO a7 | |
| AR035068A1 (es) | Compuestos de pirimidinona, composiciones farmaceuticas que los comprenden, uso de tales compuestos en la fabricacion de medicamentos y proceso para la preparacion de dichos compuestos | |
| CO5690582A2 (es) | Derivados de n-tiazol-2-il-benzamida | |
| PE109598A1 (es) | Pirrolcarboxamidas condensadas, utiles como ligandos de receptores cerebrales gaba | |
| PE20100737A1 (es) | Nuevos compuestos | |
| PE20030761A1 (es) | Derivados del 7-amino-benzotiazol | |
| PE20020844A1 (es) | Derivados de imidazolilo como inhibidores del factor de liberacion de la corticotropina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |